This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Usability and Feasibility of a Personalized, Web-based Education and Self-management Approach for Patients With Chronic Heart Failure Across Four European Sites

Sponsored by Maastricht University Medical Center

About this trial

Last updated 2 years ago

Study ID

NL75892.068.20

Status

Recruiting

Type

Observational

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 2 years ago

What is this trial about?

The STABELISE-HF is an investigator initiated, international, multicentre feasibility study that will investigate the use of a web application called SanaCoach Heart failure in patients with chronic heart failure. SanaCoach heart failure provides patient education, systematic self-monitoring, a care plan repository and facilitates correspondence with patient's care provider.

What are the participation requirements?

Yes

Inclusion Criteria

- Adults (≥18 years) that own a device where SanaCoach heart failure can be used on

- Diagnosis of chronic heart failure according to ESC 2016 guidelines (HFrEF = LVEF <40%, HFmrEF = LVEF 40-49%, HFpEF = LVEF ≥ 50%), based on echocardiographic or MRI findings within the last year or considered stable before.

- Ability and willingness to give written informed consent and to comply with the requirements of the study

No

Exclusion Criteria

- Patients without access to a device where SanaCoach heart failure can be used on

- Uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk (according to investigator's [or delegate] judgment) if he/she participates in the clinical study.

- Patients that have been hospitalised for heart failure within the last 30 days.

- An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results.

- Treatment with other investigational products or devices within 30 days or five half-lives of the screening visit, whichever is longer.

- Planned use of other investigational products or devices during the course of the study.

- Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:

- a. Subjects who are unable to communicate or to cooperate with the investigator.

- b. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.

- c. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (eg, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study).

- d. Have any medical or surgical condition, which in the opinion of the investigator would put the subject at increased risk from participating in the study

- e. Persons directly involved in the conduct of the study.

Locations

Location

Status

Recruiting
Recruiting
Recruiting
Recruiting
Recruiting